Edwards Lifesciences Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss increased by 150.0% to $500.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 400.0%, from $100.00K to $500.00K. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss shows a downward trend with a -64.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests rising interest rates or market volatility impacting the short-term valuation of the investment portfolio.
Represents the total accumulated unrealized losses on available-for-sale debt securities that have been in a continuous...
Standard disclosure for financial institutions under GAAP; peers typically report this in the investment securities note.
other_debt_securities_available_for_sale_continuous_unre_d33b47| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.20M | $2.10M | $11.90M | $48.80M | $62.10M | $48.00M | $8.10M | $1.00M | $1.00M | $400.00K | $1.90M | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $200.00K | $500.00K |
| QoQ Change | — | +75.0% | +466.7% | +310.1% | +27.3% | -22.7% | -83.1% | -87.7% | +0.0% | -60.0% | +375.0% | -94.7% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +100.0% | +150.0% |
| YoY Change | — | — | — | — | >999% | >999% | -31.9% | -98.0% | -98.4% | -99.2% | -76.5% | -90.0% | -90.0% | -75.0% | -94.7% | +0.0% | +0.0% | +0.0% | +100.0% | +400.0% |